Inhibitors of rho associated coiled-coil containing protein kinase
A technology of R12 and R13, which can be used in medical preparations containing active ingredients, drug combinations, cardiovascular system diseases, etc., and can solve problems such as hindering the penetration of small molecule inhibitors
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0305] All solvents and reagents were commercially available and used as received. Recorded on the Bruker instrument (300MHz or 400MHz) in the deuterated solvent 1 H NMR spectrum. Chemical shifts are given in ppm and coupling constants are given in Hertz. By flash chromatography using 220-400 mesh silica gel or by reverse phase HPLC with CH 3 CN / water was used as solvent to purify all final compounds. Thin layer chromatography was performed on silica gel 60F-254 (0.25 nm thickness) plates. Visualization was accomplished with UV light and / or 10% phosphomolybdic acid in ethanol. Nominal (low resolution) mass spectra were acquired on a Waters LCT or Applied Biosystems API 3000 mass spectrometer. High resolution mass spectra (HRMS) were acquired on Waters LCT or Agilent TOF mass spectrometers. All other LC-MS experiments were performed on an Agilent 1100HPLC coupled to an Agilent single quadrupole mass spectrometer. Compound purity was determined by LC-MS at wavelengths of ...
Embodiment 2
[0342] N-(1H-indazol-5-yl)-2-(methylamino)-2-phenylacetamide
[0343]
[0344] The reaction was carried out according to general scheme A. The final residue was purified by reverse phase preparative HPLC to afford N-(lH-indazol-5-yl)-2-(methylamino)-2-phenylacetamide (80%) as an off-white solid. 1 H NMR (400MHz, CD 3 OD) δ8.34 (s, 1H), 8.27 (s, 1H), 7.68-7.65 (m, 2H), 7.60-7.53 (m, 5H), 5.1 (s, 1H), 2.69 (s, 3H). MS (ES+) m / e 281.1 (M+H).
Embodiment 3
[0346] N-(1H-indazol-5-yl)-1,2,3,4-tetrahydroquinoline-3-carboxamide
[0347]
[0348] The reaction was carried out according to general scheme A. The final residue was purified by reverse-phase preparative HPLC to give N-(1H-indazol-5-yl)-1,2,3,4-tetrahydroquinoline-3-carboxamide (23% ). 1 H NMR (400MHz, MeOD-d 3 )δ13.75(s,1H),10.84(s,1H),8.94(s,1H),8.80(s,1H),8.26(m,2H),7.71(m,2H),7.28(m,2H ), 6.63(s,1H), 4.21(m,1H), 3.97(m,1H), 3.65(m,3H). MS(ES+)m / e293.1(M+H) + .
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com